Brines M, Patel NS, Villa P et al (2008) Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin
Retatrutide is a triple agonist targeting GLP-1, GIP, and glucagon receptors
This critical difference means it functions as a targeted lipolytic agent rather than a systemic hormone, allowing for fat metabolism enhancement without the appetite disruptions, cortisol elevation, or blood sugar effects associated with growth hormone therapy
Previous insulin use and previous glucocorticoid use were identified through redeemed prescriptions (binary variables)
The cyclized peptide is then lyophilized into 10 mg vials and held for the analytical release queue
Reduce clenching and grinding (bruxism)